君实生物(01877.HK)特瑞普利单抗治疗黑色素瘤获常规批准

阿斯达克财经
06 Jan

君实生物(01877.HK) 公布,收到国家药品监督管理局核准签发的《药品补充申请批准通知书》,特瑞普利单抗(商品名︰拓益)用于既往接受全身系统治疗失败的不可切除或转移性黑色素瘤的治疗的适应症获得国家药监局同意,由附条件批准转为常规批准。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-06 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10